David Hong, MDEnriched profile
Professor (Tenure), Department of Investigational Cancer Therapeutics, Division of Cancer Medicine; Deputy Chair, Department of Investigational Cancer Therapeutics; Associate Vice President of Clinical Research · The University of Texas MD Anderson Cancer Center
Overview
Updated 14 Jul 2026
David Hong, M.D., is Professor (Tenure), Department of Investigational Cancer Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX. The public record shows 1,978 publications with 47,734 citations (h-index 107), centered on Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics. It also documents an investigator role on 42 registered clinical trials, industry payments reported by 18 companies, 4 NIH-funded awards (2014–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Lung Cancer Treatments and Mutations
- 42 registered trials on ClinicalTrials.gov
- Open Payments reporting from 18 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 67 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 531.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 42 registered studies on ClinicalTrials.gov. The most recent:
- Phase II: Engagement and Clinical Impact of the Teleo Virtual Therapy Platform in Clinical Settings
Sponsor: Stanford University
InvestigatorRecruitingNCT07155707 - A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Sponsor: Verastem, Inc.
InvestigatorPhase 1/PHASE2RecruitingNCT07020221 - Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)
Sponsor: National Cancer Institute (NCI)
InvestigatorPhase 2Active, not recruitingNCT06390852
Industry payments
Updated 14 Jul 2026
18 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20252 payments$19,723openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year20251 payment$10,240openpaymentsdata.cms.gov ↗
- Janssen Global Services, LLCProgram year20251 payment
NIH funding
Updated 14 Jul 2026
4 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:
- Research Training for Child Psychiatry and Neurodevelopment
Stanford University
FY2026$344,085T32MH019908 - Engagement and clinical impact of the Teleo virtual therapy platform in clinical settings
Mainsquare Co
FY2025$1,240,774R42MH136878
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Convergence of KRAS Mutations and MTAP Loss in Pancreatic Cancer: Genomic Landscape and Clinical Implications.
Clinical cancer research
2026
Most-cited worksby citation count (OpenAlex)
- 01
- 02The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity2,260 citations2019
- 03KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors1,694 citations2020
- 04
- 05
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aaadv.org ↗
- BA/BS
Yale University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aaadv.org ↗
Editorial & leadership rolesjournal and society appointments
- Deputy Chair
Department of Investigational Cancer Therapeutics (Phase I Program), MD Anderson
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aumbiosciences.com ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pancan.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aumbiosciences.com ↗
Secondary affiliationsappointments beyond the home institution
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mdanderson.org ↗
- Clinical Medical Director
Clinical Center for Targeted Therapy, MD Anderson
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →darwinresearch.com ↗ - Associate Editor
Investigational New Drugs (journal editorial board)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →link.springer.com ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →leerink.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →darwinresearch.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- LinkedIn
linkedin.com/in/david-s-hong-md-7317851
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - X / Twitter
x.com/davidhongmd
- ResearchGate
researchgate.net/profile/David-Hong-8
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by otherswhere others cite or feature them
- Other
leerink.com/podcast/david-hong-md-steve-potts-phd-mba-and-vivek-subbiah-md-talk-pan-tumor-approvals-in-a-post-ira-world
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →leerink.com ↗ - Other
ajmc.com/view/dr-david-s-hong-we-are-learning-every-day-about-cellular-therapies
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ajmc.com ↗ - Other
darwinresearch.com/episode-44
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →darwinresearch.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
- 5,579
- publications
- 233
- h-index
- 24
- trials
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
- 1,905
- publications
- 187
- h-index
- 1
- trial
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
- 1,745
- publications
- 154
- h-index
- 22
- trials
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
- 2,643
- publications
- 148
- h-index
- 8
- trials